Journal
Blood Advances
Publication Date
10-11-2023
Volume
7
Issue
20
First Page
6009
Last Page
6022
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2023010032
Rights and Permissions
O'Neal J, Cooper ML, Ritchey JK, Gladney S, Niswonger J, González LS, Street E, Haas GJ, Carter A, Amayta PN, Gao F, Lee BH, Choi D, Berrien-Elliott M, Zhou A, Fehniger TA, Rettig MP, DiPersio JF. Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc. Blood Adv. 2023 Oct 24;7(20):6009-6022. doi: 10.1182/bloodadvances.2023010032. © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
O'Neal, Julie; Cooper, Matthew L; Ritchey, Julie K; Gladney, Susan; Niswonger, Jessica; González, L Sofía; Street, Emily; Haas, Gabriel J; Carter, Alun; Amayta, Parmeshwar N; Gao, Feng; Berrien-Elliott, Melissa; Zhou, Alice; Fehniger, Todd A; Rettig, Mike P; DiPersio, John F; and et al., "Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc." Blood Advances. 7, 20. 6009 - 6022. (2023).
https://digitalcommons.wustl.edu/oa_4/3001
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
